OpenLB
Open Library of Bioscience
Advanced Search

Journal

Publication Year

1 year 3 years 5 years 10 years
2021 - 2032
202120222023
202420252026
202720282029
203020312032
2021 - 2032
202120222023
202420252026
202720282029
203020312032

Publication Type

Associated Data

Found 309 results

Filters: Lantus

[Clinical use of lantus (glargin insulin) in Moscow endocrinological service: analysis of efficiency and safety].
М В Antsiferov, L G Dorofeyeva, О М Koteshkova, N A Kolerova, D A Gorelova, Y V Petraneva
Probl Endokrinol (Mosk). Dec 15, 2005.51(6):24-30 Electronic
Source:PubMed
PMID: 31627496 doi:10.14341/probl200551624-30
Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Michael F Crutchlow, John S Palcza, Kate M Mostoller, Chantal D Mahon, April M Barbour, Michael C Marcos, Yang Xu, Elaine Watkins, Linda Morrow, Marcus Hompesch
Diabetes Obes Metab. 02, 2018.20(2):400-408 Print-Electronic
Source:PubMed
PMID: 28817223 doi:10.1111/dom.13084
[LEAP (Lantus Early Access Programme) in Sarajevo].
Bećir Heljić, Zelija Velija-Asimi, Azra Bureković, Belma Buturović, Armana Cerić, Bosanko Horozić, Dijana Sakambet, Amela Dizdarević-Bostandzić, Ismana Surković, Snjezana Hasanbegović, Dragan Stevanović
Med Arh. 2005.59(5):283-5 Print
Source:PubMed
PMID: 16134746 doi:
Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring.
Huiying Wang, Yunting Zhou, Xiaofang Zhai, Bo Ding, Ting Jing, Xiaofei Su, Huiqin Li, Jianhua Ma
Front Endocrinol (Lausanne). 2021.12:754820 Electronic-eCollection
Source:PubMed
PMID: 34917025 doi:10.3389/fendo.2021.754820
In Brief: Rezvoglar - another insulin glargine product interchangeable with Lantus.
No authors listed
Med Lett Drugs Ther. 04 03, 2023.65(1673):56 Print
Source:PubMed
PMID: 37020341 doi:10.58347/tml.2023.1673c
[My quality of life has increased with Lantus].
Henrikvon Euler
Lakartidningen. Sep 23, 2004.101(39):3015; discussion 3016 Print
Source:PubMed
PMID: 15493645 doi:
Clinical effectiveness of Novolin® 30R versus Lantus® combined with Glucobay® treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglycaemic agents: A randomized study.
Yixuan Sun, Li Shao, Xianping Niu, Yue Liu, Jianli Ge, Hua Jiang, Hua Zhang
J Int Med Res. Aug, 2014.42(4):993-1001 Print-Electronic
Source:PubMed
PMID: 24925584 doi:10.1177/0300060514529555
Lantus overdose: case presentation and management options.
Everett T Fuller, Michael A Miller, David W Kaylor, Cliff Janke
J Emerg Med. Jan, 2009.36(1):26-9 Print-Electronic
Source:PubMed
PMID: 17976762 doi:10.1016/j.jemermed.2007.02.038
A comparison of clinical efficacy and economic value in Basalin- and Lantus-treated patients with type 2 diabetes using continuous glucose monitoring system.
H Q Li, C F Lu, J Wang, G P Yin, R Sun, X H Xu, B L Liu, F F Li, T Jing, K O Lee, L Ye, J H Ma, X F Su
J Endocrinol Invest. Feb, 2018.41(2):179-184 Print-Electronic
Source:PubMed
PMID: 28643298 doi:10.1007/s40618-017-0712-0
Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review.
Xia Hu, Lei Zhang, Yanhu Dong, Chao Dong, Jikang Jiang, Weiguo Gao
F1000Res. 2018.7:477 Electronic-eCollection
Source:PubMed
PMID: 29862021 doi:10.12688/f1000research.13923.1
0